Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development.

"I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executive Officer. "His track record of success in developing strategies that have resulted in global approvals for some of the world's most important cancer drugs make him a strong fit for Halozyme. We look forward to benefiting from his expertise and counsel as we execute our strategy to advance PEGPH20 in multiple tumor settings and expand Enhanze™ collaborations."

Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In this position, Dr. Bizzari was responsible for Celgene's clinical development and operations-statistics teams across the US, Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of the company's management committee.

Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute and is a board member of Transgene. Jean-Pierre Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.

Halozyme Therapeutics is a biopharmaceutical company that develops and commercializes products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company has partnerships with Roche, Pfizer, Janssen and Baxter. Halozyme is headquartered in San Diego, CA.